Distribusion Technologies | $80,000,000 | (Sep 27, 2024)
Cytix | $2,143,528 | (Sep 27, 2024)
Convergence | $12,000,000 | (Sep 27, 2024)
Certified by Founder
Lodge
Epsilogen Ltd
start up
United Kingdom
- Hammersmith
- 10/09/2024
- Series B
- $16,370,899
Epsilogen is a global leader in the development of immunoglobulin (IgE) antibodies to treat cancer. IgE has several key features that make it ideal for the treatment of solid tumours including greater potency, enhanced tumour access and a long tissue half-life.
The company's lead programme targets the folate receptor alpha (FR alpha) and an anti-FR alpha IgE antibody is currently in a phase I trial to treat ovarian cancer. This is the world's first IgE therapeutic to enter the clinic.
- Industry Biotechnology
- Website https://epsilogen.com/
- LinkedIn https://www.linkedin.com/company/epsilogen-ltd/
Related People
Tim WilsonFounder
United Kingdom -
London, England
Seasoned biotechnology executive with 30 years of experience in start ups, venture capital, investment banking and equity research in Europe and the US.
SURGAR | $12,288,870 | (Sep 27, 2024)
Quorum | Undisclosed Amount | (Sep 27, 2024)
Prepared | $27,000,000 | (Sep 27, 2024)
AmpUp | $15,000,000 | (Sep 27, 2024)
HighFive | $250,000 | (Sep 27, 2024)
Tetrix | $5,000,000 | (Sep 27, 2024)
The Curling Group | $5,000,000 | (Sep 27, 2024)
AminoChain | $5,000,000 | (Sep 27, 2024)
Gladly | $40,000,000 | (Sep 27, 2024)